Medtronic — Sep 1, 2026 release

Key Highlights • Revenue of $9.8 billion, increased 13.7% as reported and 13.7% organic, roughly 200 basis points above guidance midpoint • GAAP diluted EPS of $1.14; non-GAAP diluted EPS of $1.45, ahead of guidance • Raising FY27 organic revenue growth guidance 50 basis points to 7.25% to 7.75%, and FY27 diluted non-GAAP EPS guidance to the new range of $5.94 to $6.00 • Cardiovascular grew 18.9%, led by 15% growth in Cardiac Rhythm Management and 88% growth in Cardiac Ablation Solutions 1 • Announced expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias • Announces strategic investment in Pi-Cardia, a pioneer in leaflet modification technology • Neuroscience grew 9.3%, driven by 13% growth in Cranial and Spinal Technologies, including low-20s growth in enabling technology; Altaviva meaningfully contributed to 15% growth in Pelvic Health • Medical Surgical reported strong performance, up 10.2%, led by 9% growth in Surgical and 14% growth in Acute Care & Monitoring • Announces strategic partnership with Cornerstone Robotics to further expand global access to robotic-assisted surgery • Announced FDA clearance for Touch Surgery™ Aide next generation computing platform • Completed acquisitions of Scientia Vascular and SPR Therapeutics, Inc. “We are off to a strong start in fiscal 2027. What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platf